DEF6 deficiency, a mendelian susceptibility to EBV infection, lymphoma, and autoimmunity - 04/02/21
Doi : 10.1016/j.jaci.2020.05.052
Benjamin Fournier, MD a, b, ∗, Maud Tusseau, MSc c, ∗, Marine Villard, PhD d, Christophe Malcus, PharmD, PhD e, Emilie Chopin, MSc f, Emmanuel Martin, PhD a, b, Debora Jorge Cordeiro, PharmD a, b, Nicole Fabien, PharmD, PhD d, Mathieu Fusaro, PharmD a, g, Alexandra Gauthier, MD h, Nathalie Garnier, MD h, David Goncalves, PharmD d, Sonia Lounis, MSc a, b, Christelle Lenoir, MSc a, b, Anne-Laure Mathieu, PhD c, Marion Moreews, MSc c, Magali Perret, MSc d, Capucine Picard, MD, PhD a, b, g, Cécile Picard, MD i, Françoise Poitevin, PharmD e, Sébastien Viel, PharmD, PhD c, d, Yves Bertrand, MD, PhD c, h, Thierry Walzer, PhD c, Alexandre Belot, MD, PhD c, j, k, ‡ 
, Sylvain Latour, PhD a, b, ‡
, Sylvain Latour, PhD a, b, ‡ a Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR 1163, F-75015, Paris, France
b Université de Paris, Imagine Institute, F-75015, Paris, France
c International Center for Infectiology Research, Inserm U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS, UMR5308, Lyon, France
d Immunology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite, Lyon 1 University, France
e Immunology Laboratory, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
f Centre de Biotechnologie Cellulaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Bron, France
g Study Center for Primary Immunodeficiencies, Assistance Publique Hôpitaux de Paris, Necker-Enfants Malades Hospital, F-75015, Paris, France
h Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon, France
i Institut de Pathologie Multisite, Groupement Hospitalier Est, Hospices Civils de Lyon, UCBL Lyon 1 University, Lyon, France
j National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE), France
k Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, University Lyon I, Lyon, France
| This study was funded by the Ligue Contre le Cancer-Equipe Labellisée (France) (to S.L.), INSERM (France), Rare Diseases Foundation (to S.L.) (France), ANR-14-CE14-0028-01 (to S.L.), ANR 18-CE15-0025-01 (to S.L.), “Investissements d'avenir” program ANR-10-IAHU-01 (Imagine Institute), the Société Française Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent, AREMIG (France), Fédération Enfants et Santé (to S.L.) (France). B.F. is the recipient of a Fondation pour la Recherche Médicale fellowship (FDM20170638301) (France). D.J.C. was supported by the Imagine Institute PhD program funded by the Fondation Bettencourt Schueller. S.L. is a senior scientist at the Centre National de la Recherche Scientifique-CNRS (France). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 147 - N° 2
P. 740 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Heterozygous IKK? activation loop mutation results in a complex immunodeficiency syndrome
- Jordan Abbott, Angelica C. Ehler, Divya Jayaraman, Paul R. Reynolds, Kanao Otsu, Laurie Manka, Erwin W. Gelfand
- ITK deficiency presenting as autoimmune lymphoproliferative syndrome
- Jacqueline G. Wallace, Mohammed F. Alosaimi, Claudia Djambas Khayat, Faris Jaber, Abduarahman Almutairi, Sarah Beaussant-Cohen, Geraldine Pinkus, Mark Fleming, Cybel Mehawej, Janet Chou, Raif S. Geha
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?